Sana Idrees, MD
Retina Specialist · Rochester, NYNPI 1316332489
Payments from drug & device makers
What this record shows
Alcon accounts for 69.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $1,552 and has fallen 87.9% since, to $188 in 2025. That places this record below the midpoint for retina specialist clinicians in NY, where the typical reported total is $2,298.
Across 33 payments — averaging $67.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Regeneron Healthcare Solutions, Inc.$241
- Biogen$100
- Apellis Pharmaceuticals, Inc.$96
- Astellas Pharma US Inc$77
- Alimera Sciences, Inc.$72
- plus $102 from 4 others
What the payments were for
- Travel & lodging$1,21154%
- Food & beverage$1,02846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 5 | $1,552 |
| Regeneron Healthcare Solutions, Inc. | 8 | $241 |
| Biogen | 1 | $100 |
| Apellis Pharmaceuticals, Inc. | 5 | $96 |
| Astellas Pharma US Inc | 5 | $77 |
| Alimera Sciences, Inc. | 4 | $72 |
| AbbVie | 2 | $35 |
| Genentech USA, Inc. | 1 | $34 |
| Harrow Eye, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,239 in reported general payments places this provider in the 45th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 31 | $6,729 |
| ProlensaBromfenac Sodium | 14 | $4,684 |
| Prednisolone Acetate | 46 | $2,352 |
| Difluprednate | 28 | $2,202 |
| Atropine Sulfate | 30 | $899 |
| Ketorolac Tromethamine | 42 | $819 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $746 |
| Brimonidine Tartrate | 11 | $715 |
| Latanoprost | 30 | $366 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $306 |
| ErythromycinErythromycin Base | 15 | $132 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Rochester
- Matthew WitmerRochester$62K
- Edward HallRochester$38K
- Brian ConnollyRochester$7K
- Steven RoseRochester$5K
- Vikas KhetanRochester$3K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.